copolymers bearing fluorescein isothiocvanate accumulated in vascularised stromal regions. particularly in new growth sites at the tumour periphery. Treatment of mice with doxorubicin-HPMA copolymer conjugate achieved treated control lifespans up to 320% (three doses of 27 mg of doxorubicin equivalent per kg) compared with only 13300o using aggressive regimens of free doxorubicin (3 x 5 mg kg-').
The pharmacokinetics of doxorubicin is modified following covalent conjugation to a copolymer based on V-(2-hydroxvpropyl)methacrvlamide (HPMA) (Figure 1 ) (Duncan. 1992 ).
The doxorubicin-HPMA copolymer conjugate is unable to diffuse through cellular membranes and consequently displays a lower volume of distribution and longer plasma half-life than free doxorubicin (Seymour et al.. 1990 ). The poor membrane permeability of the conjugate also prevents its entry into cardiac tissue. reflected in decreased cardiotoxicity and permitting administration of increased doses of doxorubicin as a polymer conjugate (Yeung et al.. 1991) .
The doxorubicin-HPMA copolymer conjugate has been shown to be essentially non-cytotoxic in vitro but to mediate anti-cancer activity against a range of animal tumour models in vivo. thought to result from proteolytic activation of the conjugate within tumour tissue (Duncan et al.. 1992) . This proposed mode of action means that the activity of the drug conjugate is likely to be influenced by various biological factors. including biochemical and physiological features of the tumour.
Cassidy et al. (1989) and Duncan et al. (1992) used highperformance liquid chromatographic (HPLC) techniques to show that anthracycline-HPMA copolymer conjugates achieved high intratumoral levels of drug within established subcutaneous Walker sarcoma tumours. suggesting an ability of the drug conjugate to accumulate passively within solid tumours. However the Walker tumour is known to possess a relatively permeable vascular system (Butler et al.. 1975) . and it is not clear whether passive tumour tropism and the consequent elevated tumour levels of drug is a significant component of the mechanism of action of these anthracycline-HPMA copolymer conjugates against other solid tumours.
In this study we (Rihova et al.. 1989) : the material used in this study had a weight-average molecular weight (MW) of 24.000. and polydispersity (ratio of weight and number average-molecular weight) of 1.3. as determined by Sepharose 4B 6B gel permeation chromatography. Doxorubicin content was 7.2% (w w) (2.5 mol%). To permit radioiodination an HPMA copolymer conjugate of doxorubicin was synthesised with similar specifications to contain also methacryloylated tyrosinamide as a comonomer (.Omol%. component X, Figure la) (Chytry et al.. 1987) .
Radiolabelling was performed with International. UK) using a solid phase oxidising agent (lodobeads. Pierce Chemicals. Rockford. USA) as described elsewhere (Seymour et al., 1991 glycyl glycine 4-nitrophenyl ester (MA-GlyGly-ONp) in acetone as described elsewhere (Rihova et al., 1989) . The polymeric precursor had MW 34,900 and polydispersity 1.44, and the molar ratio of MA-GlyGly-ONp to HPMA monomer units was 2 mol%.
Subsequently aminolysis of ONp groups of the polymeric precursor with a 100-fold molar excess of ethylenediamine was used to prepare P-GlyGly-HN-(CH2)-NH2 as follows.
Polymeric precursor (0.7 g), dissolved in freshly distilled DMF (4.0 ml), was added dropwise to a solution of 1.6 ml of ethylenediamine in 3 ml of DMF at room temperature. The reaction mixture was stirred for 2 h, the solvent and ethylenediamine were evaporated under vacuum, 2 ml of methanol was added and the polymer was isolated by precipitation into a mixture of acetone-diethyl ether (1:1, v,,v) and purified by 2-fold reprecipitation of the polymer from methanol solution into acetone-diethyl ether.
P-GlyGly-HN-(CH2)2-NH, (0.3 g) was then dissolved in DMF (2.0 ml), FITC (0.156 g in 0.15 ml of DMF) added and the mixture was stirred for 6 h. P-GlyGly-HN-(CH2)2-NH-FITC was isolated by precipitation into acetone and purified by double precipitation from methanol into acetone. Final purification was carried out using a Sephadex G25 column and then the product, containing 1 mol% FITC, was lyophilised. (with a doxorubicin content of 5 or 18mgkg-') in saline (0.1 ml), animals were sacrificed (30min to 48 h) and tumours immediately isolated, weighed and frozen. For determination of doxorubicin levels, tumours were subsequently homogenised in known total volumes of phosphatebuffered saline, and then daunomycin (200 ng) was added to aliquot portions to act as an internal standard, prior to extraction into three volumes of chloroform-propan-2-ol (3:1, v/v). The organic phase was separated by centrifugation, decanted off and dried under nitrogen. The residue was redissolved in methanol (100 l) for HPLC analysis using a reversed phase 1i-Bondapak C,8 column, with mobile phase of propan-2-ol (29%, v/v) in water, adjusted to pH 3.2 with orthophosphoric acid. Anthracyclines were detected by fluorescence (A 480 nm, A 560 nm) and the size of the daunomycin peak was used to quantify the amount of doxorubicin present.
HPLC quantification of total doxorubicin, including doxorubicin-HPMA copolymer conjugate, first required liberation of the aglycone form of the drug from the copolymer by acid-hydrolysis cleavage of the intramolecular glycosidic bond. This method is known to give accurate determination of polymer-bound doxorubicin (Seymour et al., 1990) . Following careful neutralisation the sample was processed as described above. Doxorubicin levels in tumours are expressed as ng of doxorubicin per g of tumour tissue, and full methodological details are given elsewhere (Seymour et al., 1990 Figure  2a ). although this treatment resulted in no measurable weight loss or other signs of toxicity. Therefore animals were also treated with higher doses of doxorubicin-HPMA copolymer conjugate (three daily doses of up to 36 mg kg-') and the optimum dose level was found to be 27 mg kg-', which achieved a median lifespan of 320% compared with untreated controls (Figure 2b (Figure 3a and b) . When an equivalent dose of doxorubicin was administered as HPMA copolymer conjugate, total doxorubicin levels measured in the tumour rose to 7.5 iLg g-' after 1 h. At first all of the tumour-associated drug was present in HPMA copolymerconjugated form (Figure 3a ), but subsequently free drug was released from the carrier (Figure 3b) (Table I) . Treatment of tumour-bearing C57 mice with a single dose of doxorubicin-HPMA copolymer conjugate, containing 18 gg-1 doxorubicin, produced total doxorubicin levels in the tumour over 20 tLg g'l ( Figure 3a ) and free drug levels up to 0.9 Lg g-' (Figure 3b ). The AUCs for free and total doxorubicin concentrations in the tumour over the first 48 h were 40.1 iLg h g' and 671.7 ;Lg h g l respectively, representing increases of 360% and 7,603% compared with those achieved following administration of 5 mg kg-' free doxorubicin (Table I) . Figure 3c shows the levels of radioactivity measured in the tumour following i.v. administration of doxorubicin-HPMA copolymer conjugate (containing 5 mg kg-' doxorubicin. and with a trace of radiolabelled conjugate). Data (Duncan et al., 1988 (Duncan et al., , 1989 (Duncan et al., , 1992 (Seymour et al., 1994) . This resulted in tumour loclisation of up to 5% of the administered dose per g tumour, 10-15 times more than that achieved using free doxorubicin administered at equal doses (5 mg of doxorubicin per kg). Decreased toxicity of the polymer-conjugated doxorubcin permitted use of elevated doses, and single injections of doxorubicin-HPMA copolymer conjugate bearing 18 mg of doxorubicin per kg achieved tumour levels of drug 45-fold higher than those resulting from the standard 5 mg kg-' dose of free doxorubicin.
Following injection of doxorubicin-HPMA copolymer conjugate (containing 5 mg of doxorubicin equivalent per kg), HPLC analysis showed that levels of tumour-associated doxorubicin (including copolymer-bound doxorubicin) showed an initial rapid rise and reached a peak between 1 and 6 h ( Figure 3b ). Studies using radiolabelled doxorubicin-HPMA copolymer conjugate confirmed rapid tumour accumulation immediately following administration, although tumour levels of radioactivity continued to rise steadily over 12 h (Figure 3c (Jain, 1990) . This leads to poor oxygenation of the tumour mass, and induces the release of angiogenic and capillarypermeabilising factors such as vascular endothelial growth factor in order to improve the supply of oxygen and nutrients (Ferrara et al., 1992) . The increased permeability of tumour vasculature also facilitates extravasation of macromoleules, including copolymer-drug conjugates, from the bloodstream into the tumour interstitium. However many of these macromolecules are unable to return to the circulation via the lymphatics, instead frequently remaining and accumulating within the tumour. This phenomenon of passive tumour tropism of soluble macromolecules and drug conjugates has been described before and termed the enhanced permeability and retention (EPR) effect (Matsumura & Maeda, 1986; Seymour, 1992) . The mechanism of anti-cancer activity of doxorubicin-HPMA copolymer conjugate may depend on its modified pharmacokinetics, notably its relative accumulation within tumours. Despite encouraging preclinical evidence, however, it remains unclear whether this phenomenon is typical of human clinical disease, including slowly growing tumours. Tumour-imaging using gallium-67 has been suggested to result from the accumulation of transferrin-bound isotope within tumour tissue (Maeda, 1991) , and may also depend on the EPR effect described above. The usefulness of gallium-67 in imaging lymphomas (Hodgkin's and non-Hodgkin's; Johnston et al., 1974) , hepatomas (Suzuki et al., 1971) and certain other solid carcinomas (Nelson et al.. 1972) suggests that the phenomenon may be of clinical relevance, with polymerbound drugs consequently finding a number of therapeutic applications.
